- Biome Australia (ASX:BIO) starts delivering its first allocation of Activated Probiotics into pharmacy and health retail stores across the UK and Ireland
- The allocation follows the recent signing of commercial agreements with UK-based CLF and Ireland-based iiHealthfood, which are to be stocked across the regions
- The European launch builds on BIO’s success in the Australian market, where it applied an education model and practitioner-only distribution
- Through commercial testing of both markets, Biome acquires a strong foundational customer and revenue base to be confident that both markets have been de-risked
- BIO shares are up 14.6 per cent, trading at 27.5 cents at 2:22 pm AEDT
Biome Australia (ASX:BIO) has started delivering its first allocation of Activated Probiotics into pharmacy and health retail stores across the United Kingdom and the Republic of Ireland.
The allocation follows the recent signing of commercial agreements with UK-based CLF and Ireland-based iiHealthfood, intended to be stocked at multiple distribution centres for nationwide consumption.
The European launch builds on the company’s success with activated probiotics in the Australian market, where it applied an education model and practitioner-only distribution. Biome’s team intends to manage all aspects of training, support and customer service to ensure the sales model is consistent with the Australian market.
“This is a significant achievement and demonstrates our ability to both execute and scale into new international markets,” BIO Managing Director and founder Blair Norfolk said.
“We are confident that we have the right elements in place for these markets to add material value to the Biome business over coming years and will also strengthen our ability to support new patients, improve their health outcomes, and quality of life and make our products accessible to all – that remains our core mission.”
Following a successful test market phase in both countries with a focus on independent health practitioners, Biome has acquired a strong foundational customer and revenue base to be confident that both markets have been sufficiently de-risked.
BIO shares were up 14.6 per cent, trading at 27.5 cents at 2:22 pm AEDT.